HPV
MCID: HMN048
MIFTS: 46

Human Papillomavirus Infectious Disease (HPV)

Categories: Cancer diseases, Infectious diseases, Oral diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Human Papillomavirus Infectious Disease

MalaCards integrated aliases for Human Papillomavirus Infectious Disease:

Name: Human Papillomavirus Infectious Disease 12
Hpv 12 42
Human Papilloma Virus Infection 17
Papillomavirus Infections 44

Classifications:



External Ids:

Disease Ontology 12 DOID:11166
MeSH 44 D030361

Summaries for Human Papillomavirus Infectious Disease

MedlinePlus : 42 What is HPV? Human papillomavirus (HPV) is a group of related viruses. They can cause warts on different parts of your body. There are more than 200 types. About 40 of them are spread through direct sexual contact with someone who has the virus. They can also spread through other intimate, skin-to-skin contact. Some of these types can cause cancer. There are two categories of sexually transmitted HPV. Low-risk HPV can cause warts on or around your genitals, anus, mouth, or throat. High-risk HPV can cause various cancers: Cervical cancer Anal cancer Some types of oral and throat cancer Vulvar cancer Vaginal cancer Penile cancer Most HPV infections go away on their own and don't cause cancer. But sometimes the infections last longer. When a high-risk HPV infection lasts for many years, it can lead to cell changes. If these changes are not treated, they may get worse over time and become cancer. Who is at risk for HPV infections? HPV infections are very common. Nearly all sexually active people are infected with HPV soon after they become sexually active. What are the symptoms of HPV infections? Some people develop warts from certain low-risk HPV infections, but the other types (including the high-risk types) have no symptoms. If a high-risk HPV infection lasts for many years and causes cell changes, you may have symptoms. You may also have symptoms if those cell changes develop into cancer. Which symptoms you have depends on which part of the body is affected. How are HPV infections diagnosed? Health care providers can usually diagnose warts by looking at them. For women, there are cervical cancer screening tests which can find changes in the cervix that might lead to cancer. As part of the screening, women may have Pap tests, HPV tests , or both. What are the treatments for HPV infections? An HPV infection itself cannot be treated. There are medicines that you can apply to a wart. If they don't work, your health care provide could freeze, burn, or surgically remove it. There are treatments for the cell changes caused by infection with high-risk HPV. They include medicines that you apply to the area that is affected and various surgical procedures. People who have HPV-related cancers usually get the same types of treatment as people who have cancers that are not caused by HPV. An exception to this is for people who have certain oral and throat cancers. They may have different treatment options. Can HPV infections be prevented? Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading HPV. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Vaccines can protect against several types of HPV, including some that can cause cancer. The vaccines provide the most protection when people get them before they are exposed to the virus. This means that it is best for people to get them before they become sexually active. NIH: National Cancer Institute

MalaCards based summary : Human Papillomavirus Infectious Disease, also known as hpv, is related to squamous cell papilloma and anus cancer. An important gene associated with Human Papillomavirus Infectious Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and PI3K-Akt signaling pathway. The drugs Polihexanide and Aluminum hydroxide have been mentioned in the context of this disorder. Affiliated tissues include cervix, skin and eye, and related phenotypes are digestive/alimentary and neoplasm

Disease Ontology : 12 A viral infectious disease that has material basis in human papillomaviruses, which establish productive infections only in the stratified epithelium of the skin or mucous membranes. These viruses cause warts and sometimes tumors. They are transmitted by sexual contact.

Wikipedia : 73 Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a... more...

Related Diseases for Human Papillomavirus Infectious Disease

Diseases related to Human Papillomavirus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 710)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 32.4 TP53 CDKN2A
2 anus cancer 32.1 TP53 CDKN2A
3 anogenital venereal wart 32.0 TP53 IFNB1 CDKN2A
4 penile cancer 31.9 TP53 TERT CDKN2A
5 cervix uteri carcinoma in situ 31.8 TP53 FHIT CDKN2A
6 anal canal carcinoma 31.8 KRT13 CDKN2A
7 vaginal cancer 31.8 TP53 CDKN2A
8 vulva cancer 31.8 TP53 KRT13 CDKN2A
9 cervical cancer 31.7 TP53 TERT FHIT CDKN2A CDKN1A
10 cervical intraepithelial neoplasia 31.7 TERT FHIT CDKN2A
11 squamous cell carcinoma 31.6 TP53 FHIT CDKN2A CDKN1A
12 squamous cell carcinoma, head and neck 31.5 TP53 FHIT CDKN2A CDKN1A
13 oral cancer 31.2 TP53 KRT13 FHIT CDKN2A CDKN1A
14 suppressor of tumorigenicity 3 31.2 TP53 FHIT CDKN2A CDKN1A
15 vulvar intraepithelial neoplasia 31.1 TP53 CDKN2A
16 vulva squamous cell carcinoma 31.0 TP53 CDKN2A
17 papilloma 31.0 TP53 KRT13 FLG CDKN2A CDKN1A
18 chronic cervicitis 30.9 TP53 CDKN2A
19 verrucous carcinoma 30.9 TP53 CDKN2A
20 cervical adenocarcinoma 30.9 TP53 CDKN2A CDKN1A
21 anal squamous cell carcinoma 30.7 TP53 CDKN2A
22 endocervical adenocarcinoma 30.6 TP53 CDKN2A CDKN1A
23 larynx cancer 30.6 TP53 TERT CDKN2A
24 inverted papilloma 30.5 TP53 KRT13 CDKN2A
25 leukoplakia 30.5 KRT13 FLG
26 keratinizing squamous cell carcinoma 30.4 TP53 CDKN2A
27 tonsil cancer 30.4 TP53 CDKN2A
28 keratosis 30.4 TP53 FLG CDKN2A
29 cervix carcinoma 30.3 TP53 FHIT CDKN2A
30 bowenoid papulosis 30.3 TERT FLG CDKN2A
31 basaloid squamous cell carcinoma 30.2 TP53 KRT13 CDKN2A
32 laryngeal squamous cell carcinoma 30.2 TP53 TERT FHIT CDKN2A
33 keratoacanthoma 30.1 TP53 FLG CDKN1A
34 hypopharynx cancer 30.1 TP53 CDKN2A
35 actinic keratosis 30.0 TP53 FLG CDKN2A
36 skin papilloma 29.9 TP53 CDKN1A
37 endocervical carcinoma 29.9 TP53 CDKN2A
38 nasopharyngeal carcinoma 29.9 TP53 TERT KRT13 CDKN2A
39 keratosis, seborrheic 29.9 TP53 CDKN2A
40 lichen planus 29.9 TP53 KRT13 FLG
41 vulvar disease 29.9 TP53 KRT13 CDKN2A
42 colorectal adenocarcinoma 29.8 TP53 TERT CDKN2A
43 acanthoma 29.8 TP53 CDKN2A
44 esophageal cancer 29.8 TP53 TERT FHIT CDKN2A CDKN1A
45 penile benign neoplasm 29.8 TP53 CDKN2A
46 kaposi sarcoma 29.8 TP53 IFNB1 CDKN1A
47 anus disease 29.8 TP53 CDKN2A
48 malignant spiradenoma 29.8 TP53 CDKN2A
49 basal cell carcinoma 29.8 TP53 TERT CDKN2A CDKN1A
50 bladder urothelial carcinoma 29.7 TP53 FHIT CDKN2A

Graphical network of the top 20 diseases related to Human Papillomavirus Infectious Disease:



Diseases related to Human Papillomavirus Infectious Disease

Symptoms & Phenotypes for Human Papillomavirus Infectious Disease

MGI Mouse Phenotypes related to Human Papillomavirus Infectious Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 CDKN1A CDKN2A FHIT KRT13 TERT TP53
2 neoplasm MP:0002006 9.1 CDKN1A CDKN2A FHIT IFNB1 TERT TP53

Drugs & Therapeutics for Human Papillomavirus Infectious Disease

Drugs for Human Papillomavirus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polihexanide Approved, Investigational Phase 4 28757-47-3
2
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
3 Biguanides Phase 4
4 Pharmaceutical Solutions Phase 4
5 Vaccines Phase 4
6 Monophosphoryl lipid A Phase 4
7
Eugenol Approved Phase 3 97-53-0 3314
8
Lactitol Approved, Investigational Phase 3 585-86-4 157355
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
acetic acid Approved Phase 3 64-19-7 176
11
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
12
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
13
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
14 Antiviral Agents Phase 3
15 Immunologic Factors Phase 3
16 Olive Phase 3
17 Interferon alpha-2 Phase 2, Phase 3
18 Gastrointestinal Agents Phase 3
19 Cathartics Phase 3
20 Laxatives Phase 3
21 Immunosuppressive Agents Phase 3
22 Antimetabolites Phase 3
23
Retinol acetate Phase 3 127-47-9 10245972
24 Anesthetics Phase 3
25 interferons Phase 3
26 Adjuvants, Immunologic Phase 3
27
Cidofovir Approved Phase 2 113852-37-2 60613
28
Sodium citrate Approved, Investigational Phase 2 68-04-2
29
Nitric Oxide Approved Phase 2 10102-43-9 145068
30
Catechin Approved, Withdrawn Phase 2 154-23-4 9064
31
Cantharidin Approved, Investigational Phase 2 56-25-7
32
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
33
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
34
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
35
Durvalumab Approved, Investigational Phase 2 1428935-60-7
36
Artesunate Approved, Investigational Phase 2 88495-63-0 5464098 6917864
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
39
Hydroxyurea Approved Phase 2 127-07-1 3657
40
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
41
Ipilimumab Approved Phase 2 477202-00-9
42
Pembrolizumab Approved Phase 2 1374853-91-4
43
Lenvatinib Approved, Investigational Phase 2 417716-92-8
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
46
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
47
Epicatechin Investigational Phase 2 490-46-0 72276
48
Epigallocatechin Experimental, Investigational Phase 2 970-74-1 72277
49
Ranpirnase Investigational Phase 1, Phase 2 196488-72-9
50 retinol Phase 2

Interventional clinical trials:

(show top 50) (show all 297)
# Name Status NCT ID Phase Drugs
1 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
2 Acceptability and Feasibility of a Modified HPV Vaccine Schedule in Brothel Based Female Sex Workers in Peru Completed NCT00925288 Phase 4
3 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
4 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
5 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
6 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
7 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
8 Acceptance and Completion Rate of Free HPV Vaccination Among Underserved Adult Patients (Age 18-45) Recruiting NCT04474821 Phase 4
9 Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students Recruiting NCT04459221 Phase 4 Gardasil 9, 9-Valent Intramuscular Suspension
10 Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. Recruiting NCT04232917 Phase 4 2LPAPI®;Placebo
11 An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination Regimen Over 6 Months Among Women Aged 16 to 45 Years Old, An Exploratory Immunogenicity Study Recruiting NCT04206813 Phase 4 Gardasil 9 2 dose regimen;Gardasil 9 3 dose regimen;Gardasil 9 rescue dose
12 Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women. Recruiting NCT04270773 Phase 4
13 KENya Single-dose HPV-vaccine Efficacy - The KEN-SHE Study Active, not recruiting NCT03675256 Phase 4
14 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study ("Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)") Active, not recruiting NCT03180034 Phase 4
15 Evaluation of HPV Vaccine Immunity in High-risk Women: a Pilot Study Not yet recruiting NCT04590521 Phase 4
16 Immunogenicity of Fractional Dose of the Bivalent and Nonavalent Intradermal HPV Vaccines. Not yet recruiting NCT04235257 Phase 4
17 A Phase 4, Randomized, Open Label Clinical Trial to Determine Efficacy and Immunomodulation of Simultaneous HPV/HBV Vaccination Tango-trial) Terminated NCT01082861 Phase 4
18 A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
19 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
20 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Unknown status NCT02733068 Phase 3
21 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
22 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
23 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
24 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3
25 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
26 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
27 Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India Completed NCT00380367 Phase 3
28 An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea Completed NCT00157950 Phase 3
29 A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls Completed NCT01254643 Phase 3
30 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
31 An Immunogenicity and Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years Completed NCT00496626 Phase 3
32 Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa Completed NCT01245764 Phase 3
33 A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds) Completed NCT01073293 Phase 3
34 A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men and Women Completed NCT01461096 Phase 3
35 A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) Given Concomitantly With Menactra™ and Adacel™ in Preadolescents and Adolescents (11 to 15 Year Olds) Completed NCT00988884 Phase 3
36 Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens Completed NCT00973362 Phase 3
37 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Completed NCT01984697 Phase 3
38 a Multi-sites, Randomized, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection Completed NCT01824992 Phase 2, Phase 3 Yallaferon®
39 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
40 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
41 A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study). Completed NCT00092547 Phase 3
42 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
43 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
44 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
45 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
46 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
47 A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents Completed NCT00518180 Phase 3
48 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
49 A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen With Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared With a Standard 3-dose Regimen in 16- to 26-Year Old Women Recruiting NCT04708041 Phase 3
50 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil

Search NIH Clinical Center for Human Papillomavirus Infectious Disease

Cochrane evidence based reviews: papillomavirus infections

Genetic Tests for Human Papillomavirus Infectious Disease

Anatomical Context for Human Papillomavirus Infectious Disease

MalaCards organs/tissues related to Human Papillomavirus Infectious Disease:

40
Cervix, Skin, Eye, Kidney, Bone Marrow, Bone, Lymph Node

Publications for Human Papillomavirus Infectious Disease

Articles related to Human Papillomavirus Infectious Disease:

(show top 50) (show all 793)
# Title Authors PMID Year
1
Update on human papillomavirus - Part II: complementary diagnosis, treatment and prophylaxis. 42
33637397 2021
2
Patient-Derived Organotypic Epithelial Rafts Model Phenotypes in Juvenile-Onset Recurrent Respiratory Papillomatosis. 42
33418959 2021
3
Detection of high-risk human papillomavirus (HPV) by the novel AmpFire isothermal HPV assay among pregnant women in Pemba Island, Tanzania. 42
33447338 2020
4
High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. 54 61
8015113 1994
5
Cytokines in the treatment of virus infections. 61 54
7865346 1994
6
High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. 61 54
8402668 1993
7
The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018. 61
33492104 2021
8
Increased Burden of Concordant and Sequential Anogenital Human Papillomavirus Infections Among Asian Young Adult Women With Perinatally Acquired HIV Compared With HIV-Negative Peers. 61
32976361 2021
9
Prevalence and Concordance of Oral HPV Infections with Cervical HPV Infections in Women Referred to Colposcopy with Abnormal Cytology. 61
33733523 2021
10
Site and sex-specific differences in the effect of vitamin D on human papillomavirus infections: analyses of NHANES 2009-2014. 61
32234963 2021
11
The environmental pollutant and tobacco smoke constituent dibenzo[def,p]chrysene is a co-factor for malignant progression of mouse oral papillomavirus infections. 61
33186600 2021
12
Correlation between multi-type human papillomavirus infections and viral loads and the cervical pathological grade. 61
33020921 2021
13
Canine Papillomavirus 2 E6 Does Not Interfere With UVB-Induced Upregulation of p53 and p53-Regulated Genes. 61
33748203 2021
14
[Squamous cell carcinoma arising in oral lichen planus : Report of two cases]. 61
32820361 2020
15
Vaccinating both girls and boys can eliminate human papillomavirus infections. 61
32701191 2020
16
Prevalence of oral human papillomavirus infections by race in the United States: An association with sexual behavior. 61
32011771 2020
17
Successful treatment of genital warts with cidofovir cream in a pediatric patient with Fanconi anemia. 61
31718429 2020
18
Progression Low Squamous Intraepithelial Lesion and Human Papillomavirus Infections. 61
32843861 2020
19
Abrogation of Constitutive and Induced Type I and Type III Interferons and Interferon-Stimulated Genes in Keratinocytes by Canine Papillomavirus 2 E6 and E7. 61
32585804 2020
20
Persistence and clearance of oral human papillomavirus infections: A prospective population-based cohort study. 61
32492214 2020
21
Identification of Multiple High-Risk Human Papillomavirus Infections in a Rural Population of Canatlan, Durango, Mexico. 61
32429752 2020
22
Discrepancy Between Personal Experience and Negative Opinion with Human Papillomavirus Vaccine in Web Forums. 61
32604691 2020
23
An Infection-Based Murine Model for Papillomavirus-Associated Head and Neck Cancer. 61
32398315 2020
24
Stress-induced Interaction of Skin Immune Cells, Hormones, and Neurotransmitters. 61
32276734 2020
25
The Changing Spectrum of Sexually Transmitted Infections in Europe. 61
32207537 2020
26
Cellular immune responses against natural human papillomavirus infections among men in Kisumu, Kenya. 61
31054968 2020
27
The Interplay between Antiviral Signalling and Carcinogenesis in Human Papillomavirus Infections. 61
32164347 2020
28
'Cryo-immuno-therapy' is superior to intralesional Candida antigen monotherapy in the treatment of multiple common warts. 61
32009473 2020
29
Cervicovaginal Microbiome and Urine Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with Human Papilloma Virus Infections. 61
31952112 2020
30
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study. 61
33373380 2020
31
Human Papillomavirus Infections in Cervical Samples From HIV-Positive Women: Evaluation of the Presence of the Nonavalent HPV Genotypes and Genetic Diversity. 61
33324386 2020
32
[Policies vaccination against the Human papillomavirus infections in France and worldwide]. 61
32877038 2020
33
The Penile Microbiota in Uncircumcised and Circumcised Men: Relationships With HIV and Human Papillomavirus Infections and Cervicovaginal Microbiota. 61
32850898 2020
34
High prevalent human papillomavirus infections of the oral cavity of asymptomatic HIV-positive men. 61
31924186 2020
35
Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment. 61
31968015 2020
36
Self-Collected Specimens Revealed a Higher Vaccine- and Non-Vaccine-Type Human Papillomavirus Prevalences in a Cross-Sectional Study in Akuse. 61
32411484 2020
37
Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance. 61
31666385 2020
38
Human Papillomavirus Infections, Cervical Cancer and MicroRNAs: An Overview and Implications for Public Health. 61
31738147 2020
39
The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis. 61
32670296 2020
40
Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. 61
32647779 2020
41
Oral isotretinoin for treating mucocutaneous human papillomavirus infections: A systematic review and meta-analysis. 61
31274470 2019
42
Anal human papillomavirus infections in young unvaccinated men who have sex with men attending a sexual health clinic for HPV vaccination in Melbourne, Australia. 61
31521414 2019
43
16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. 61
31409912 2019
44
Instruments for quality of life assessment in individuals with human papillomavirus. 61
31531663 2019
45
Effect of Geographic Isolation on the Nasal Virome of Indigenous Children. 61
31189707 2019
46
Canine papillomavirus types 1 and 2 in classical papillomas: High abundance, different morphological associations and frequent co-infections. 61
31383413 2019
47
Persistence rate of cervical human papillomavirus infections and abnormal cytology in Rwanda. 61
31318136 2019
48
Chlorin, Phthalocyanine, and Porphyrin Types Derivatives in Phototreatment of Cutaneous Manifestations: A Review. 61
31398812 2019
49
mSphere of Influence: Stromal Regulation of Epithelium Containing Viral Oncogenes. 61
31315968 2019
50
Extracellular events impacting human papillomavirus infections: Epithelial wounding to cell signaling involved in virus entry. 61
30981651 2019

Variations for Human Papillomavirus Infectious Disease

Expression for Human Papillomavirus Infectious Disease

Search GEO for disease gene expression data for Human Papillomavirus Infectious Disease.

Pathways for Human Papillomavirus Infectious Disease

Pathways related to Human Papillomavirus Infectious Disease according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 TP53 IFNB1 CDKN2A CDKN1A
2
Show member pathways
12.74 TP53 TERT IFNB1 CDKN1A
3
Show member pathways
12.68 TP53 IFNB1 CDKN2A CDKN1A
4 12.57 TP53 TERT CDKN2A CDKN1A
5
Show member pathways
12.49 TP53 TERT CDKN2A CDKN1A
6
Show member pathways
12.36 TP53 FHIT CDKN2A CDKN1A
7 12.32 TP53 CDKN2A CDKN1A
8 12.29 TP53 CDKN2A CDKN1A
9
Show member pathways
12.16 TP53 CDKN2A CDKN1A
10 12.15 TP53 CDKN2A CDKN1A
11
Show member pathways
12.13 TP53 CDKN2A CDKN1A
12 12.08 TP53 CDKN2A CDKN1A
13 11.93 TP53 CDKN2A CDKN1A
14 11.84 TP53 TERT CDKN1A
15 11.8 TP53 TERT CDKN2A CDKN1A
16 11.73 TP53 CDKN2A CDKN1A
17 11.7 TP53 CDKN2A CDKN1A
18 11.54 TP53 FHIT CDKN1A
19 11.48 TP53 CDKN2A CDKN1A
20 11.41 TP53 CDKN2A CDKN1A
21 11.36 TP53 CDKN2A CDKN1A
22 11.31 TP53 CDKN1A
23 11.29 TP53 CDKN1A
24 11.22 TP53 CDKN1A
25 11.14 TP53 CDKN2A CDKN1A
26 11.13 TP53 CDKN2A
27 11.13 TP53 CDKN1A
28 10.95 TP53 IFNB1 CDKN2A CDKN1A
29 10.92 TP53 CDKN2A
30 10.59 TP53 CDKN1A
31
Show member pathways
10.47 TP53 CDKN2A CDKN1A
32
Show member pathways
10.34 TP53 CDKN1A

GO Terms for Human Papillomavirus Infectious Disease

Cellular components related to Human Papillomavirus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.17 TP53 TERT KRT13 FLG FHIT CDKN2A

Biological processes related to Human Papillomavirus Infectious Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.79 TP53 TERT CDKN1A
2 cytokine-mediated signaling pathway GO:0019221 9.78 TP53 IFNB1 CDKN1A
3 protein stabilization GO:0050821 9.67 TP53 CDKN2A CDKN1A
4 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.6 TP53 TERT
5 cellular response to ionizing radiation GO:0071479 9.59 TP53 CDKN1A
6 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 CDKN2A CDKN1A
7 positive regulation of cell cycle arrest GO:0071158 9.58 TP53 CDKN2A
8 positive regulation of reactive oxygen species metabolic process GO:2000379 9.57 TP53 CDKN1A
9 intrinsic apoptotic signaling pathway GO:0097193 9.56 TP53 CDKN1A
10 cellular response to gamma radiation GO:0071480 9.55 TP53 CDKN1A
11 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.54 TP53 CDKN1A
12 cell cycle arrest GO:0007050 9.54 TP53 CDKN2A CDKN1A
13 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.52 TP53 FHIT
14 cellular senescence GO:0090398 9.51 CDKN2A CDKN1A
15 negative regulation of cell growth GO:0030308 9.5 TP53 CDKN2A CDKN1A
16 response to X-ray GO:0010165 9.48 TP53 CDKN1A
17 negative regulation of phosphorylation GO:0042326 9.46 CDKN2A CDKN1A
18 mitotic cell cycle arrest GO:0071850 9.43 TP53 CDKN1A
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.4 TP53 CDKN1A
20 Ras protein signal transduction GO:0007265 9.33 TP53 CDKN2A CDKN1A
21 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.26 TP53 TERT
22 signal transduction by p53 class mediator GO:0072331 8.96 TP53 CDKN1A
23 replicative senescence GO:0090399 8.92 TP53 TERT CDKN2A CDKN1A

Molecular functions related to Human Papillomavirus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.43 TP53 FHIT CDKN1A
2 disordered domain specific binding GO:0097718 9.16 TP53 CDKN2A
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN2A CDKN1A
4 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A

Sources for Human Papillomavirus Infectious Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....